Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ADRENOCORTICAL CARCINOMA, HEREDITARY

Known as: ADCC 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Adrenocortical carcinoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2018
Review
2018
The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
ABSTRACT Therapeutic monoclonal antibodies are the fastest growing class of biological therapeutics for the treatment of various… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
The human epidermal growth factor receptor (HER) family plays an important role in cell survival and proliferation, and is… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
Cetuximab (Erbitux, IMC‐C225) is a monoclonal antibody targeted to the epidermal growth factor receptor (EGFR). To clarify the… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Trastuzumab is a recombinant antibody drug that is widely used for the treatment of breast cancer. Despite encouraging clinical… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity
Purpose: The use of the CD20-specific antibody rituximab has greatly improved the response to treatment of CD20+ follicular… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms
Rituximab (IDEC-C2B8, Mabthera(R)) is a chimeric (human-mouse) monoclonal antibody (MoAb) against the B-cell specific CD20… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
The glycosylation pattern of chCE7, an antineuroblastoma chimeric IgG1, was engineered in Chinese hamster ovary cells with… Expand
  • figure 2
  • figure 1
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
1994
Highly Cited
1994
High frequency of germline p53 mutations in childhood adrenocortical cancer.
BACKGROUND Adrenocortical carcinoma (ADCC) is a rare childhood cancer, affecting three of 1 million children younger than 16… Expand
Is this relevant?
Review
1988
Review
1988
Opioid peptides and opioid receptors in cells of the immune system.
I Abbreviations used: ACTH, adrenocorticotropic hormone; ADCC, antibody-dependent cellular cytotoxicity; Bma .. total number of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE